Understanding how a specific mutation leads to blood cancers.
Official title: Molecular Basis for Progression of Myeloproliferative Neoplasms Induced by JAK2V617F
Funded at University of Virginia · NIH-11057744 · Data updated 2026-11-12
This study is looking into how a specific gene mutation affects blood cancers called myeloproliferative neoplasms (MPNs) and aims to find new ways to improve treatments, which could help patients like you feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | January 15, 2025 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $601,169 |
| NIH project number | 1R01HL173611-01A1 |
| Project ID | NIH-11057744 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with the JAK2V617F mutation.
✕Less likely to help
Patients with other types of blood cancers that do not involve the JAK2V617F mutation may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms behind myeloproliferative neoplasms (MPNs), a group of blood cancers characterized by the overproduction of blood cells. It focuses on the JAK2V617F mutation, which is prevalent in many cases of these conditions, and aims to identify new therapeutic targets to improve treatment outcomes. By studying the deletion of chromosome 20q and its role in the progression of these cancers, the research seeks to uncover potential tumor suppressor genes that could lead to better therapies. Patients may benefit from insights that could lead to more effective treatments for MPNs.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that more effectively treat myeloproliferative neoplasms.
How similar studies have gone: Previous research has shown promise in targeting similar molecular pathways in blood cancers, indicating potential for success in this area.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Mohi, Golam — University of Virginia
- Study coordinator: Mohi, Golam
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.